Although PD-L1 expression in tumor tissue has been related to response to PD-1 blockade, a systematic evaluation of 45 FDA-approved trials involving 15 tumor types demonstrated that PD-L1 expression was predictive in only 28.9% of cases [6]. This evidence concerns the gene CD274 and neoplasm.